STEP
WHAT HAPPENS
MOLECULES
DEFECT → DISEASE
Gene segments for variable regions cut and joined; ~10¹¹ possible receptors
RAG1/RAG2 (recombinase), Artemis, DNA-PK
RAG/Artemis loss → SCID (T⁻B⁻NK⁺); partial → Omenn syndrome
Random nucleotides added at joints
TdT
TdT ⁺ marks lymphoblasts (ALL)
Only one heavy- and one light-chain allele expressed per B cell
—
Each B cell makes one specificity
Marrow progenitors enter thymus; CD4⁻CD8⁻
Notch, IL-7 (IL-7R, common γ chain, JAK3)
IL-7R / γc / JAK3 defects → SCID (T⁻B⁺NK⁻ for γc, JAK3)
TCR rearranged; CD4⁺CD8⁺
—
—
Positive selection (cortex)
Thymocytes that bind self-MHC on cortical epithelial cells survive; most die by neglect
MHC I → CD8⁺ · MHC II → CD4⁺
Bare lymphocyte syndrome (no MHC II) → few CD4⁺ cells
Negative selection (medulla)
Strong binding to self-peptide on medullary cells/DCs → apoptosis
AIRE drives expression of tissue-specific antigens
AIRE loss → APS-1 (mucocutaneous candidiasis, hypoparathyroidism, Addison)
Moderately self-reactive cells become Tregs
FOXP3, CD25, IL-2, IL-10, TGF-β
FOXP3 loss → IPEX (enteropathy, diabetes, eczema)
Heavy chain rearranged first; μ chain pairs with surrogate light chain (pre-BCR)
BTK signaling
BTK loss → XLA (no mature B cells)
Light chain rearranged; surface IgM; self-reactive cells edited, deleted or made anergic
Receptor editing (new light chain)
Central B-cell tolerance
IgM + IgD (alternative splicing); leaves marrow to follicles
CD19, CD20, CD21
Rituximab targets CD20
Anergy (signal 1 without B7–CD28), Tregs, deletion (Fas–FasL), immune privilege
CTLA-4, PD-1, Fas
Fas defect → autoimmune lymphoproliferative syndrome